REGULATORY
1st Committee to Discuss Approval of New Products Including Janssen’s Extended Release Schizophrenia Treatment
The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) First Committee on Drugs, an advisory organ to the health minister, will discuss whether to approve a number of products including Janssen Pharmaceutical’s schizophrenia treatment paliperidone palmitate, a long acting injectable formulation,…
To read the full story
REGULATORY
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
- LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





